Cellectis S.A (ALCLS) | Stock Overview & Key Data
Cellectis S.A Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €41.95 on November 2, 2015
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cellectis S.A
ALCLS
|
335.97M Mid-cap | -7.81% | -6.65% | -13.24% | -27.52% | -30.09% | 131.58% | 63.83% | -74.42% | -89.63% | -48.49% | -48.49% |
|
Abivax SA
ABVX
|
7.61B Large-cap | -42.53% | -36.96% | -36.65% | -37.89% | -45.13% | 2,047.73% | 517.65% | 305.72% | 1,019.45% | 447.83% | 447.83% |
|
Nanobiotix
NANO
|
1.39B Large-cap | -11.60% | 17.87% | 15.35% | 78.02% | 64.53% | 827.52% | 612.13% | 134.60% | 81.06% | 449.03% | 449.03% |
|
Inventiva S.A
IVA
|
980.10M Mid-cap | -23.96% | -20.28% | -34.84% | -5.46% | -14.57% | 48.61% | 29.31% | -63.10% | -48.37% | -48.37% | -48.37% |
|
Medincell S.A
MEDCL
|
831.60M Mid-cap | 0.52% | 9.38% | 21.36% | 21.36% | 21.36% | 27.30% | 27.30% | 27.30% | 27.30% | 27.30% | 27.30% |
|
BNP Paribas Easy
BLUE
|
527.29M Mid-cap | -0.06% | 1.08% | -1.71% | 9.24% | 7.01% | 12.41% | 26.15% | 34.21% | -11.41% | -16.16% | -16.16% |
Ownership & Short Interest
Calculate Your Cellectis S.A Investment Returns
Long-Term Investment Performance Analysis
Cellectis S.A stock price in May 2016 was €29.71, A €1,000.00 lump sum investment in Cellectis S.A made 10 years ago would be worth approximately €90.88 today, representing a negative return of -90.91%. This translates to an annualized return (CAGR) of -21.31%.
10 Years Investment Scenario (May 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ALCLS's 52-week high and low?
- In the last 52 weeks, Cellectis S.A reached a high of €4.84 (on October 16, 2025) and a low of €1.23 (on June 19, 2025).
- What is the market cap and P/E ratio for ALCLS?
- Curious about Cellectis S.A's size and valuation? Its market capitalization stands at 335.97M. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -2.09.
- Does ALCLS pay dividends? If so, what's the yield?
- As for dividends, Cellectis S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Cellectis S.A's main competitors or similar companies to consider before investing?
When looking at Cellectis S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abivax SA
ABVX7.61B Healthcare Biotechnology 2,047.73% 517.65% Nanobiotix
NANO1.39B Healthcare Biotechnology 827.52% 612.13% Inventiva S.A
IVA980.10M Healthcare Biotechnology 48.61% 29.31% Medincell S.A
MEDCL831.60M Healthcare Biotechnology 27.30% 27.30% BNP Paribas Easy
BLUE527.29M Healthcare Biotechnology 12.41% 26.15% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Cellectis S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Cellectis S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -65.33%, the Debt to Equity ratio from the most recent quarter is 114.22, and its Gross Profit Margin stands at 71.15%.
- What is the recent revenue and earnings growth for ALCLS?
- Looking at Cellectis S.A's growth, its revenue over the trailing twelve months (TTM) was €68M. Compared to the same quarter last year (YoY), quarterly revenue grew by -19.50%, and quarterly earnings saw a YoY growth of -18.25%.
- How much of ALCLS stock is held by insiders and institutions?
- Wondering who owns Cellectis S.A stock? Company insiders (like executives and directors) hold about 48.01% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 8.74%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.